|

Prognostic Significance of ctDNA in HL

RECRUITINGSponsored by Interni hematologicka klinika FNKV
Actively Recruiting
SponsorInterni hematologicka klinika FNKV
Started2022-01-02
Est. completion2023-12-31
Eligibility
Age18 Years+
View on ClinicalTrials.gov →

NCT06263530

Summary

Specific somatic mutations using ctDNA will be analyzed in predefined subgroups of cHL (e.g., age \<60 and ≥ 60 years, EBV). These mutations will be correlated with response to the treatment in the first line, in the relapse, during brentuximab vedotin and/or nivolumab treatment. Circulating tumor DNA will be correlated with the extent of tumor mass and chemo/radiotherapy.

Eligibility

Age: 18 Years+
Inclusion Criteria:

* Patients ≥ 18 years with newly histologically confirmed classical Hodgkin lymphoma (cHL) will be enrolled
* signing the informed consent

Exclusion Criteria:

* Pacients without signing the informed consent

Conditions2

CancerPrognostic Cancer Model

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.